Concomitant i.v. and oral clodronate in the relief of bone pain--a double-blind placebo-controlled study in patients with prostate cancer.
Fifty-seven patients with advanced prostate cancer resistant to first-line hormonal therapy were treated with estramustine and additionally randomized for treatment with clodronate or placebo. Clodronate treatment was started with 5 days intravenous administration (300 mg day[-1]) and followed by oral treatment (1.6 g day[-1]) for 12 months. Skeletal pain relief was only about 10% better in the clodronate than in the placebo group. The results do not support the superiority of combined intravenous and oral treatment with clodronate compared with oral administration only.
Kylmälä
T
T
Department of Surgery, Tampere University Hospital, Finland.
Taube
T
T
Tammela
T L
TL
Risteli
L
L
Risteli
J
J
Elomaa
I
I
D000284:Administration, Oral; D000368:Aged; D000369:Aged, 80 and over; D018712:Analgesics, Non-Narcotic / Q000008:administration & dosage* / Q000009:adverse effects / Q000627:therapeutic use; D001859:Bone Neoplasms / Q000378:metabolism / Q000556:secondary*; D004002:Clodronic Acid / Q000008:administration & dosage* / Q000009:adverse effects / Q000627:therapeutic use; D003094:Collagen / Q000378:metabolism; D004311:Double-Blind Method; D006801:Humans; D007275:Injections, Intravenous; D008297:Male; D008875:Middle Aged; D010146:Pain / Q000188:drug therapy* / Q000378:metabolism; D010446:Peptide Fragments / Q000097:blood; D011347:Procollagen / Q000097:blood; D011446:Prospective Studies; D011471:Prostatic Neoplasms / Q000378:metabolism / Q000473:pathology*
D018712:Analgesics, Non-Narcotic; D010446:Peptide Fragments; D011347:Procollagen; C042813:procollagen type I carboxy terminal peptide; D004002:Clodronic Acid; D003094:Collagen